CRISPR Therapeutics, Vertex set for first sickle cell disease trial after FDA lifts clinical hold — just don't look for any explanation
CRISPR Therapeutics and Vertex have resolved a clinical hold on a high-profile gene editing program — but they’re still not ready to divulge much in the way of details about the temporary derailment they got slapped with five months ago.
The partners say the FDA has now given the green light to test their sickle cell disease treatment in humans. That will likely expand the Phase I/II study the companies are on track to initiate by the end of the year, adding to sites in the UK and Canada, where they have secured clinical trial approvals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
